Literature DB >> 26483144

Crosslinking and corneal cryotherapy in acanthamoeba keratitis -- a histological study.

Tobias Hager, A Hasenfus, T Stachon, B Seitz, N Szentmáry.   

Abstract

PURPOSE: Acanthamoeba keratitis is rare, but difficult to treat. Penetrating keratoplasty is performed in therapy-resistant cases. Nevertheless, subsequent recurrences occur in 40 % of the cases. In addition to triple-topical therapy (polyhexamid, propamidinisoethionat, neomycin), treatment alternatives are corneal cryotherapy and/or crosslinking (CXL). The aim of our present histological study was to analyze the persistence of acanthamoebatrophozoites and cysts, the persistence of bacteria, and activation of keratocytes in corneas of acanthamoeba keratitis patients following corneal cryotherapy and/or CXL. PATIENTS AND METHODS: We analyzed histologically corneal buttons (from penetrating keratoplasties) of nine patients with acanthamoeba keratitis, following corneal cryotherapy (two patients) or a combination of crosslinking and corneal cryotherapy (seven patients), using haematoxilin–eosin, periodic acid Schiff (PAS), Gram and alpha-smooth muscle actin (alpha-SMA) stainings.
RESULTS: Acanthamoeba trophozoites persisted in three corneas after cryotherapy and CXL. Cysts persisted in one of two corneas following corneal cryotherapy and in six of seven corneas after a combination of CXL and cryotherapy. One cornea showed positive Gram staining, but there were no alpha-SMA positive keratocytes in any of the corneas.
CONCLUSIONS: Crosslinking and corneal cryotherapy have only limited impact on killing of acanthamoeba trophozoites, cysts, or bacteria. Corneal cryotherapy and CXL did not stimulate myofibroblastic transformation of keratocytes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26483144     DOI: 10.1007/s00417-015-3189-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  22 in total

Review 1.  Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment.

Authors:  D V Seal
Journal:  Eye (Lond)       Date:  2003-11       Impact factor: 3.775

2.  Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates.

Authors:  María A del Buey; José A Cristóbal; Paula Casas; Pilar Goñi; Antonio Clavel; Enrique Mínguez; Elena Lanchares; Alicia García; Begoña Calvo
Journal:  Am J Ophthalmol       Date:  2011-10-11       Impact factor: 5.258

Review 3.  Safety of UVA-riboflavin cross-linking of the cornea.

Authors:  Eberhard Spoerl; Michael Mrochen; David Sliney; Stephen Trokel; Theo Seiler
Journal:  Cornea       Date:  2007-05       Impact factor: 2.651

Review 4.  Acanthamoeba keratitis: diagnosis and treatment update 2009.

Authors:  John K G Dart; Valerie P J Saw; Simon Kilvington
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

5.  The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis.

Authors:  Dana Robaei; Nicole Carnt; Darwin C Minassian; John K G Dart
Journal:  Ophthalmology       Date:  2014-03-14       Impact factor: 12.079

Review 6.  Encystation in Acanthamoeba castellanii: development of biocide resistance.

Authors:  D Lloyd; N A Turner; W Khunkitti; A C Hann; J R Furr; A D Russell
Journal:  J Eukaryot Microbiol       Date:  2001 Jan-Feb       Impact factor: 3.346

7.  Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide.

Authors:  D F Larkin; S Kilvington; J K Dart
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

8.  CD-34 stromal expression pattern in normal and altered human corneas.

Authors:  Paolo Toti; Gian Marco Tosi; Claudio Traversi; Karin Schürfeld; Concetta Cardone; Aldo Caporossi
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

9.  Clinical characteristics of Acanthamoeba keratitis infections in 28 states, 2008 to 2011.

Authors:  Jonathan Ross; Sharon L Roy; William D Mathers; David C Ritterband; Jonathan S Yoder; Tracy Ayers; Rupa D Shah; Monika E Samper; Carolyn Y Shih; Ann Schmitz; Allison C Brown
Journal:  Cornea       Date:  2014-02       Impact factor: 2.651

10.  In vitro amoebacidal activity of photodynamic therapy on Acanthamoeba.

Authors:  Z Chen; S Xuguang; W Zhiqun; L Ran
Journal:  Br J Ophthalmol       Date:  2008-09       Impact factor: 4.638

View more
  3 in total

1.  [The German Acanthamoeba keratitis register: Initial results of a multicenter study].

Authors:  L Daas; N Szentmáry; T Eppig; A Langenbucher; A Hasenfus; M Roth; M Saeger; B Nölle; B Lippmann; D Böhringer; T Reinhard; C Kelbsch; E Messmer; U Pleyer; S Roters; A Zhivov; K Engelmann; J Schrecker; L Zumhagen; H Thieme; R Darawsha; T Meyer-Ter-Vehn; B Dick; I Görsch; M Hermel; M Kohlhaas; B Seitz
Journal:  Ophthalmologe       Date:  2015-09       Impact factor: 1.059

Review 2.  Acanthamoeba keratitis - Clinical signs, differential diagnosis and treatment.

Authors:  Nóra Szentmáry; Loay Daas; Lei Shi; Kornelia Lenke Laurik; Sabine Lepper; Georgia Milioti; Berthold Seitz
Journal:  J Curr Ophthalmol       Date:  2018-10-19

3.  The Effect of Anti-Amoebic Agents and Ce6-PDT on Acanthamoeba castellanii Trophozoites and Cysts, In Vitro.

Authors:  Lei Shi; Vithusan Muthukumar; Tanja Stachon; Lorenz Latta; Mohamed Ibrahem Elhawy; Gubesh Gunaratnam; Erika Orosz; Berthold Seitz; Albrecht F Kiderlen; Markus Bischoff; Nóra Szentmáry
Journal:  Transl Vis Sci Technol       Date:  2020-11-23       Impact factor: 3.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.